Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGAL biomarker study of iopamidol versus iodixanol in PCI patients with normal kidney function
2010-019013-13Phase 4Completed
- Sponsor
- Bracco Imaging
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of iopamidol and iodixanol in acute kidney failure (AKF) and contrast-induced nephropathy (CIN) (2 arms), sponsored by Bracco Imaging. Primary endpoints: Serum NGAL trajectory and Urinary NGAL trajectory. Started Nov 2010; status: completed.
02
Drugs
iopamidoliodixanol
03
Conditions
acute kidney failure (AKF)contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on 2010-019013-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019013-13.